Massachusetts
Requires Coverage of Comprehensive Biomarker Testing
No
Highlighted Disparity
Asian or Pacific Islander individuals in Massachusetts are least likely to be diagnosed early
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases in Massachusetts is 56.3 and significantly higher than the national rate of 52.8.
- Massachusetts ranks 30th among all states, placing it in the average tier.
- Over the last five years, the rate of new cases in Massachusetts improved by 19%.
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer is 29.7% nationally.
- Massachusetts is one of the 12 states for which survival data is not available, as they do not track cases after diagnosis.
Early Diagnosis:
- In Massachusetts, 35.3% of cases are caught at an early stage, which is significantly higher than the national rate of 28.1%.
- Massachusetts ranks 2nd among the 50 states with data on early-stage diagnosis, placing it in the top tier.
- Over the last five years, the early diagnosis rate in Massachusetts improved by 7%.
Lung Cancer Treatment
Biomarker Coverage:
- Massachusetts has yet to require any insurance coverage of comprehensive biomarker testing, including for lung cancer, as of August 2025.
Surgical Treatment:
- Massachusetts ranked 1st (out of 49 states with available data) with 31.9% of cases undergoing surgery as part of the first course of treatment, which is significantly higher than the national rate of 20.7%.
- This places Massachusetts in the top tier.
- Over the last five years, the percent of cases undergoing surgery in Massachusetts did not change significantly.
No Treatment:
- Massachusetts ranked 1st (out of 49 states with available data) with 13.2% of cases not receiving any treatment, which is significantly lower than the national rate of 21.0%.
- This places Massachusetts in the top tier.
- Over the last five years, the percent of cases receiving no treatment in Massachusetts increased by 40%.
Screening
Screening for High Risk:
- In Massachusetts, 26.8% of those at high risk were screened, which is significantly higher than the national rate of 18.2%.
- Massachusetts ranks 3rd among all states, placing it in the top tier.
Prevention
Tobacco Use:
- The 2023 smoking rate in Massachusetts is 9.8% and significantly lower than the national rate of 11.4%.
- Massachusetts ranks 10th among all states, placing it in the above average tier.
Radon Exposure:
- In Massachusetts, 21.8% of radon test results were at or above the action level recommended by the EPA.
- Massachusetts ranks 25th among all states, placing it in the average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 42.6 per 100,000 population among Black individuals in Massachusetts, significantly lower than the rate of 54.2 among Black individuals nationally, and significantly lower than the rate of 59.3 among white individuals in Massachusetts.
- Survival rates by race and ethnicity are not available for Massachusetts at this time. Nationally, the five-year survival rate among Black individuals is 27.1%, 9% lower than among white Americans.
- 32.2% of lung cancer cases are diagnosed at an early stage among Black individuals in Massachusetts, significantly higher than the rate of 25.1% among Black individuals nationally, and significantly lower than the rate of 35.7% among white individuals in Massachusetts.
- 26.5% of Black individuals with lung cancer in Massachusetts underwent surgery, significantly higher than the rate of 17.1% among Black individuals nationally, and significantly lower than the rate of 31.9% among white individuals in Massachusetts.
- 13.5% of Black individuals with lung cancer in Massachusetts did not receive any treatment, significantly lower than the rate of 22.7% among Black individuals nationally, and not significantly different than the rate of 13.2% among white individuals in Massachusetts.
Latino individuals:
- The rate of new lung cancer cases is 31.8 per 100,000 population among Latino individuals in Massachusetts, significantly higher than the rate of 27.9 among Latino individuals nationally, and significantly lower than the rate of 59.3 among white individuals in Massachusetts.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
- 34.1% of lung cancer cases are diagnosed at an early stage among Latino individuals in Massachusetts, significantly higher than the rate of 23.9% among Latino individuals nationally, and not significantly different than the rate of 35.7% among white individuals in Massachusetts.
- 33.7% of Latino individuals with lung cancer in Massachusetts underwent surgery, significantly higher than the rate of 21.4% among Latino individuals nationally, and not significantly different than the rate of 31.9% among white individuals in Massachusetts.
- 13.6% of Latino individuals with lung cancer in Massachusetts did not receive any treatment, significantly lower than the rate of 25.8% among Latino individuals nationally, and not significantly different than the rate of 13.2% among white individuals in Massachusetts.
Asian Americans or Pacific Islanders:
- The rate of new lung cancer cases is 37.7 per 100,000 population among Asian or Pacific Islanders individuals in Massachusetts, significantly higher than the rate of 32.5 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 59.3 among white individuals in Massachusetts.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
- 29.4% of lung cancer cases are diagnosed at an early stage among Asian or Pacific Islander individuals in Massachusetts, significantly higher than the rate of 23.7% among Asian or Pacific Islander individuals nationally, and significantly lower than the rate of 35.7% among white individuals in Massachusetts.
- 34.6% of Asian or Pacific Islander individuals with lung cancer in Massachusetts underwent surgery, significantly higher than the rate of 24.7% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 31.9% among white individuals in Massachusetts.
- 10.8% of Asian or Pacific Islander individuals with lung cancer in Massachusetts did not receive any treatment, significantly lower than the rate of 19.8% among Asian or Pacific Islander individuals nationally, and significantly lower than the rate of 13.2% among white individuals in Massachusetts.
Indigenous Peoples:
- The rate of new lung cancer cases is 28.2 per 100,000 population among Indigenous peoples (American Indians/Alaska Natives) in Massachusetts, significantly lower than the rate of 39.8 among Indigenous Peoples nationally, and significantly lower than the rate of 59.3 among white individuals in Massachusetts.
- State-level survival rates are not available for Indigenous Peoples at this time. Nationally, the five-year survival rate among Indigenous Peoples is 22.3% and not significantly different than the rate of 25.0% among white individuals.
- Other lung cancer rates are not available for Indigenous Peoples (American Indians/Alaska Natives) in Massachusetts due to too few cases over the time period to allow for accurate analysis.
Summary
Despite the early diagnosis rate in Massachusetts falling into the top tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
Massachusetts has yet to require any insurance coverage of comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
Massachusetts falls into the top tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: October 7, 2025